MX365418B - Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias. - Google Patents

Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.

Info

Publication number
MX365418B
MX365418B MX2014015665A MX2014015665A MX365418B MX 365418 B MX365418 B MX 365418B MX 2014015665 A MX2014015665 A MX 2014015665A MX 2014015665 A MX2014015665 A MX 2014015665A MX 365418 B MX365418 B MX 365418B
Authority
MX
Mexico
Prior art keywords
cancer
selection
immune response
yeast
response generating
Prior art date
Application number
MX2014015665A
Other languages
English (en)
Other versions
MX2014015665A (es
Inventor
Röder Joanna
Röder Heinrich
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of MX2014015665A publication Critical patent/MX2014015665A/es
Publication of MX365418B publication Critical patent/MX365418B/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • G01N33/6851Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001164GTPases, e.g. Ras or Rho
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50Mutagenesis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01JELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00Particle spectrometers or separator tubes
    • H01J49/0027Methods for using particle spectrometers
    • H01J49/0036Step by step routines describing the handling of the data generated during a measurement
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)

Abstract

La presente invención se refiere a un método y sistema para predecir por adelantado del tratamiento, si es probable o si no es probables que un paciente con cáncer obtenga beneficio de la administración de una terapia generadora de respuesta inmunitaria a base de levadura, que puede ser inmunoterapia a base de levadura para cáncer positivo a Ras mutada, sola o en combinación con otra terapia anti-cáncer. El método usa espectrometría de masas de una muestra del paciente extraída de sangre y una computadora configurada como un clasificador que usa un conjunto de entrenamiento de espectros marcados por clase de otros pacientes con cáncer ya sea beneficiados o no beneficiados de una terapia generadora de respuesta inmunitaria sola o en combinación con otra terapia anti-cáncer. También se describen métodos de tratamiento de un paciente con cáncer, que comprende administrar una terapia generadora de respuesta inmunitaria a base de levadura, que puede ser inmunoterapia a base de levadura para cáncer positivo a Ras mutada, a un paciente seleccionado por una prueba de acuerdo a los métodos predictivos de espectros de masa, descritos en la presente, en la cual la marca de clase para los espectros indica si es probable que el paciente se beneficie de la inmunoterapia a base de levadura.
MX2014015665A 2012-06-26 2013-03-15 Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias. MX365418B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664308P 2012-06-26 2012-06-26
US201261664329P 2012-06-26 2012-06-26
PCT/US2013/032024 WO2014003853A1 (en) 2012-06-26 2013-03-15 Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies

Publications (2)

Publication Number Publication Date
MX2014015665A MX2014015665A (es) 2015-06-17
MX365418B true MX365418B (es) 2019-06-03

Family

ID=48045749

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015665A MX365418B (es) 2012-06-26 2013-03-15 Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.

Country Status (13)

Country Link
US (2) US9653272B2 (es)
EP (1) EP2864792A1 (es)
JP (1) JP6355630B2 (es)
KR (1) KR102103319B1 (es)
CN (1) CN104685360B (es)
AU (1) AU2013281221B2 (es)
CA (1) CA2878044C (es)
HK (1) HK1209835A1 (es)
IL (1) IL236266A0 (es)
MX (1) MX365418B (es)
SG (1) SG11201408652SA (es)
TW (1) TWI639001B (es)
WO (1) WO2014003853A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014003853A1 (en) 2012-06-26 2014-01-03 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
US11594403B1 (en) 2014-12-03 2023-02-28 Biodesix Inc. Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample
CN113456812A (zh) 2015-01-09 2021-10-01 埃图比克斯公司 用于联合免疫治疗的方法和组合物
EP3286213B1 (en) 2015-04-20 2021-08-04 Etubics Corporation Methods and compositions for combination immunotherapy
US10713590B2 (en) * 2015-04-30 2020-07-14 Biodesix, Inc. Bagged filtering method for selection and deselection of features for classification
CN108601554B (zh) 2015-06-03 2022-03-08 蒙特非奥里医疗中心 用于治疗癌症和转移的低强度聚焦超声
WO2017011439A1 (en) 2015-07-13 2017-01-19 Biodesix, Inc. Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
RU2018127709A (ru) * 2016-01-22 2020-02-25 Отрэйсис, Инк. Системы и способы улучшения диагностики заболеваний
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
US11232940B2 (en) * 2016-08-02 2022-01-25 Virgin Instruments Corporation Method and apparatus for surgical monitoring using MALDI-TOF mass spectrometry
CN110383069A (zh) * 2017-01-05 2019-10-25 佰欧迪塞克斯公司 用于鉴定总体不良预后亚组中持久受益于免疫疗法的癌症患者的方法
WO2019094802A1 (en) * 2017-11-09 2019-05-16 Montefiore Medical Center Low energy immune priming for treating cancer and metastasis
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
WO2019190732A1 (en) * 2018-03-29 2019-10-03 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
WO2020167471A1 (en) * 2019-02-15 2020-08-20 Biodesix, Inc. Predictive test for identification of early stage nsclc patients at high risk of recurrence after surgery
CN110674947B (zh) * 2019-09-02 2021-02-19 三峡大学 基于Stacking集成框架的光谱特征变量选择与优化方法
CN112164448B (zh) * 2020-09-25 2021-06-22 上海市胸科医院 免疫治疗疗效预测模型训练方法、预测系统及方法和介质

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
JPS61219387A (ja) * 1985-03-27 1986-09-29 Suntory Ltd 新規な酵母プラスミドおよびその形質転換体
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
AU702517B2 (en) 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20070048860A1 (en) 1997-10-10 2007-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Carcinoembryonic antigen (CEA) peptides
US20010055589A1 (en) 1998-06-17 2001-12-27 University Of Connecticut Cancer immunotherapy improved by prior radiotherapy
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
DK1272213T3 (da) 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Mikrobielt afgivelsessystem
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1581174B1 (en) 2002-12-16 2018-04-25 GlobeImmune, Inc. Yeast-based vaccines as immunotherapy
KR101158709B1 (ko) 2004-09-06 2012-06-22 코닌클리케 필립스 일렉트로닉스 엔.브이. 오디오 신호 강화
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
JP5104306B2 (ja) 2005-07-08 2012-12-19 株式会社ニコン 固体撮像素子
CA2614884A1 (en) 2005-07-11 2007-01-18 Globeimmune, Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
JP5198290B2 (ja) 2006-02-02 2013-05-15 グローブイミューン,インコーポレイテッド 免疫反応を誘発する酵母ベースワクチン
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune Inc mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
US8024282B2 (en) 2006-03-31 2011-09-20 Biodesix, Inc. Method for reliable classification of samples in clinical diagnostics using an improved method of classification
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7858389B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
WO2008085024A1 (en) * 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
CN101730542A (zh) 2007-03-19 2010-06-09 环球免疫公司 用于靶向消除癌症靶向疗法的突变逃逸的组合物和方法
CA2727559A1 (en) 2008-06-11 2009-12-17 Nils Aage Brunner Selection of colorectal cancer patients for neo-adjuvant and adjuvant systemic anti-cancer treatment
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
WO2010080804A1 (en) * 2009-01-06 2010-07-15 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
JP5759980B2 (ja) 2009-04-17 2015-08-05 グローブイミューン,インコーポレイテッド 癌および感染症に対する免疫療法組成物の組み合わせ
JP2011001315A (ja) 2009-06-19 2011-01-06 Cellex Corp 膵臓癌の免疫療法剤
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
CA2790928A1 (en) 2010-02-24 2011-09-01 Biodesix, Inc. Cancer patient selection for administration of therapeutic agents using mass spectral analysis
WO2011115914A1 (en) 2010-03-14 2011-09-22 Globeimmune, Inc. Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP2668504A4 (en) 2011-01-28 2015-06-10 Biodesix Inc PREDICTIVE TEST FOR SELECTING PATIENTS WITH METASTATIC BREAST CANCERS TO RECEIVE HORMONE THERAPY AND POLY THERAPY
AP2013007110A0 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
HUE033491T2 (en) 2011-03-17 2017-12-28 Globeimmune Inc Yeast-Brachyury immunotherapy
JP2014523878A (ja) 2011-06-14 2014-09-18 グローブイミューン,インコーポレイテッド D型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法
MX352892B (es) 2011-08-17 2017-12-13 Globeimmune Inc Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
US20140377220A1 (en) 2011-11-23 2014-12-25 Uti Limited Partnership Gene expression signatures for staging and prognosis of prostate, breast and leukemia cancers
WO2013154422A1 (en) 2012-04-13 2013-10-17 Erasmus University Medical Center Rotterdam Biomarkers for triple negative breast cancer
AU2013267976B2 (en) * 2012-05-29 2016-06-02 Biodesix, Inc. Deep-MALDI TOF mass spectrometry of complex biological samples, e.g., serum, and uses thereof
WO2014003853A1 (en) 2012-06-26 2014-01-03 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
CH715107B1 (fr) 2018-06-18 2021-12-30 Montres Breguet Sa Mécanisme de réglage pour mécanisme d'affichage d'horlogerie à rouleau.

Also Published As

Publication number Publication date
KR20150023881A (ko) 2015-03-05
US20170271136A1 (en) 2017-09-21
US10593529B2 (en) 2020-03-17
TWI639001B (zh) 2018-10-21
JP2015528110A (ja) 2015-09-24
TW201400812A (zh) 2014-01-01
WO2014003853A1 (en) 2014-01-03
US20130344111A1 (en) 2013-12-26
SG11201408652SA (en) 2015-01-29
CN104685360B (zh) 2018-02-13
EP2864792A1 (en) 2015-04-29
AU2013281221B2 (en) 2018-05-17
KR102103319B1 (ko) 2020-04-22
AU2013281221A1 (en) 2015-02-12
CA2878044C (en) 2021-10-26
IL236266A0 (en) 2015-02-26
CN104685360A (zh) 2015-06-03
US9653272B2 (en) 2017-05-16
CA2878044A1 (en) 2014-01-03
HK1209835A1 (en) 2016-04-08
JP6355630B2 (ja) 2018-07-11
MX2014015665A (es) 2015-06-17

Similar Documents

Publication Publication Date Title
CA2878044C (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
PH12016500331A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MX366965B (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
MX349096B (es) Anticuerpos anti-pd-l1 y sus usos.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
NZ618062A (en) Hsp90 combination therapy
MY186591A (en) Methods for increasing efficacy of folri cancer therapy
WO2015035250A3 (en) Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
MX2016007903A (es) Metodos de elaboración de perfiles de epitopos de celulas t, elaboracion de composiciones de celulas t y tratamiento de enfermedades.
MX2013006758A (es) Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
EP4345110A3 (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
SG10201901391RA (en) Induction of il-12 using immunotherapy
BR112015028252A2 (pt) método de tratamento de câncer de pulmão por vacinação com lipopeptídeo muc-1
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf
WO2012019125A3 (en) Biomarkers for prostate cancer and methods for their detection
MX2014014829A (es) Anticuerpos autoinmunes.

Legal Events

Date Code Title Description
FG Grant or registration